Kai Yu was peering into the intricate architecture of a bladder tumor when he noticed something no one had seen before—not a single type of cancer cell dominating the landscape, but a carefully organized mosaic of luminal and basal-like cells, each nestled in distinct neighborhoods within the same tumor. At MD Anderson Cancer Center in Houston, Yu and his colleagues, led by Linghua Wang and Jianjun Gao, have created the first spatial map of muscle-invasive bladder cancer, revealing that tumors are not monolithic entities but complex ecosystems where cell identity, immune presence, and treatment response are all shaped by location.
This breakthrough, published in Cancer Discovery, challenges decades of thinking that classified bladder cancers simply as luminal or basal. Instead, the team found a continuous differentiation axis within tumors—cancer cells gradually shifting from luminal to basal states in a spatially organized way. Using spatial transcriptomics on 22 pretreatment tumors, combined with whole-exome and bulk RNA sequencing, they mapped how these cell states coexist and interact. Luminal-like cells, enriched with FGFR3 and NECTIN4—both targets of existing therapies—were concentrated in tumor cores. Basal-like cells, in contrast, occupied invasive margins, showing heightened EGFR signaling, epithelial-mesenchymal transition (EMT), chromosomal instability, and immune infiltration—hallmarks of aggressive disease.
The implications are profound. The study shows that a tumor’s spatial composition correlates with clinical outcomes: tumors with more basal-immune suppressive states were linked to advanced stage and poorer response to chemotherapy. This means two patients with seemingly similar diagnoses may respond very differently based on the internal geography of their tumors. “An important message from this work is that effective treatment may need to account for both luminal and basal components within the same tumor, as well as their spatial organization,” Gao said. The findings suggest future therapies could be rationally combined or sequenced—targeting luminal regions with FGFR3 inhibitors while using immunotherapies or EGFR blockers at the invasive front.
Beyond refining treatment, this spatial framework could improve patient stratification. Current biomarkers fall short in predicting response, but mapping tumor heterogeneity in space may offer a clearer picture. With single-cell and spatial validation across additional tumors, the team has laid the foundation for precision oncology that considers not just what cells are present, but where they are. As Wang puts it, “Our spatial analyses show that this binary view is incomplete.” The future of bladder cancer therapy may not lie in broader strokes, but in navigating the tumor’s hidden terrain—one region at a time.